Article
Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes.
Oncotarget - 29 Nov 2016
Boi Michela, Todaro Maria, Vurchio Valentina, Yang Shao Ning, Moon John, Kwee Ivo, Rinaldi Andrea, Pan Heng, Crescenzo Ramona, Cheng Mangeng, Cerchietti Leandro, Elemento Olivier, Riveiro Maria E, Cvitkovic Esteban, Bertoni Francesco, Inghirami Giorgio
Abstract excerpt
Anaplastic large cell lymphomas (ALCL) represent a peripheral T-cell lymphoma subgroup, stratified based on the presence or absence of anaplastic lymphoma kinase (ALK) chimeras. Although ALK-positive ALCLs have a more favorable outcome than ALK-negative ALCL, refractory and/or relapsed forms are common and novel treatments are needed. Here we investigated the therapeutic potential of a novel bromodomain...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.